Early-stage clinical trials in Quebec
The Smart Choice for You
What do you get when you combine brilliant physician-scientists, cutting-edge infrastructure, clever incentives and today’s foremost AI hub? Quite possibly the smartest ecosystem for early-stage clinical trials in the world.
public and university research centres1
contract research organizations2
graduates a year in health-related programs1
active clinical trials in 20193
companies in the life sciences industry1
- Investissement Québec (investquebec.com)
- Ministry of Economy, Science and Innovation, 2017
- Clinicaltrials.gov, September 2019
The Province of Quebec is a world leader in
early-stage clinical trials
World-class clusters in the cities of Montreal, Quebec City and Sherbrooke.
State-of-the-art hospitals and research centres that rank among the best in the world.
A universal system that combines high-quality health care with research and teaching and also simplifies patient recruitment.
An ethnically diverse population that facilitates the conduct of clinical trials in all therapeutic areas.
The lowest overall clinical trial costs in Canada and among all G7 countries4
Tax incentives that can reduce the net cost of R&D projects by almost 35%5
Foreign researchers and experts may benefit from a 5-year tax exemption.
Favourable Canadian exchange rate.
Experts that are internationally recognized for their discoveries and innovations in all therapeutic areas.
A 30-day regulatory review process and a unified ethics review framework for studies conducted in more than one public institution.
A world-leading AI hub, with top global players, more than 20 centres of excellence and more than 30 incubators and accelerators.
- KPMG Competitive Alternatives 2016
Financial Times fDiBenchmark, 2019
- Investissement Québec (investquebec.com)
Looking for smart partners for your next clinical trial?
Meet some of Quebec’s top physician-scientists
Dr. Jean-Claude Tardif | Director | Montreal Heart Institute Research Center
Scientific Director, Montreal Health Innovations Coordinating Centre (MHICC)
Dr. Tardif is a leading authority on atherosclerosis. He has contributed to the development of intravascular ultrasonography, established one of the largest clinical trial coordination centres in Canada (the MHICC), authored more than 600 scientific articles, and received the Order of Canada.
Dr. Jean-Philippe Lafrance | Nephrologist | Maisonneuve-Rosemont Hospital Research Centre
Associate Professor, Department of Pharmacology and Physiology Université de Montréal
When he’s not hiking through Quebec’s wilderness or bicycle touring with his family, Dr.
Lafrance is either doing research, teaching or monitoring kidney disease patients.
Dr. Michel Duval | Head of the Hematology-Oncology Department and clinical researcher | CHU Sainte-Justine Research Center
A cure for everyone! These words define Dr. Michel Duval’s profound motivation to conduct experimental protocols with his young patients. Because even today, “too many of them do not respond to the treatments we have for them.”
Dr. Wilson H. Miller | Director, Clinical Research Unit | Jewish General Hospital, Lady Davis Institute for Medical Research
Dr. Miller is a visionary and a rare expert in the use of molecular therapy to kill cancer cells. A native of Kansas City, he chose to settle in Quebec more than 25 years ago because he found the ideal conditions for his research work at the Jewish General Hospital and at McGill University.
Dr. André Carpentier | Director of the Diabetes, Obesity and Cardiovascular Complications Research Axis | Centre for Research at the CHUS (CRCHUS) – Université de Sherbrooke
Thanks to his lipid imaging techniques, Dr. André Carpentier can track the breakdown of dietary fats in the body. And now he wants to apply his methods to the development of drugs for metabolic syndrome and type 2 diabetes.
Dr. Angela Genge | Neurologist and Director, Clinical Research Unit | Montreal Neurological Institute and Hospital
Dr. Angela Genge is a fighter who is always on the lookout for clinical trials for patients suffering from amyotrophic lateral sclerosis (ALS) or any other rare neurodegenerative disease for which there is no satisfactory therapeutic option.
She became Director of the Amyotrophic Lateral Sclerosis Clinic at the Montreal Neurological Institute and Hospital (The Neuro) in 1998, and was appointed as head the Clinical Research Unit in 2004.
CATALIS Quebec Clinical Trials is a non-profit partnership financed by the Ministère de l’Économie et de l’Innovation du Québec